Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2592
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials” ; volume:37 ; number:8 ; day:5 ; month:9 ; year:2017 ; pages:739-740 ; date:11.2017
Journal of clinical immunology ; 37, Heft 8 (5.9.2017), 739-740, 11.2017
- Schlagwort
-
Nichtmedikamentöse Therapie
- Urheber
-
Suez, Daniel
- Beteiligte Personen und Organisationen
-
Stein, Mark
Gupta, Sudhir
Hussain, Iftikhar
Melamed, Isaac
Paris, Kenneth
Darter, Amy
Bourgeois, Christelle
Fritsch, Sandor
Leibl, Heinz
McCoy, Barbara
Gelmont, David
Yel, Leman
SpringerLink (Online service)
- DOI
-
10.1007/s10875-017-0438-y
- URN
-
urn:nbn:de:1111-201712214589
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Suez, Daniel
- Stein, Mark
- Gupta, Sudhir
- Hussain, Iftikhar
- Melamed, Isaac
- Paris, Kenneth
- Darter, Amy
- Bourgeois, Christelle
- Fritsch, Sandor
- Leibl, Heinz
- McCoy, Barbara
- Gelmont, David
- Yel, Leman
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
New Frontiers in Subcutaneous Immunoglobulin Treatment
A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
To the Editor
Letter to Editor
To the Editor
To the Editor
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
New Frontiers in Subcutaneous Immunoglobulin Treatment
A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
To the Editor
Letter to Editor
To the Editor
To the Editor
Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
New Frontiers in Subcutaneous Immunoglobulin Treatment
A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis
Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
To the Editor
Letter to Editor
To the Editor